Steven O'Day - 05 Jan 2023 Form 4 Insider Report for AGENUS INC (AGEN)

Role: Chief Medical Officer
Signature: /s/ Christine Klaskin, as attorney-in-fact for Steven O'Day
Issuer symbol: AGEN
Transactions as of: 05 Jan 2023
Net transactions value: +$267,983
Form type: 4
Filing time: 09 Jan 2023, 16:42:48 UTC
Previous filing: 04 Feb 2022
Next filing: 18 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGEN	Common Stock	Award	$267,983	+109,381	+67%	$2.45	272,384	05 Jan 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGEN	Stock Option	Award	$0	+200,000		$0.000000	200,000	05 Jan 2023	Common Stock	200,000	$2.45	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the executive's 2022 performance bonus award paid in Agenus Stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 50% of the award released on March 24, 2023 and 50% of the award released on June 24, 2023.
F2	$2.45 was the fair market value of Agenus Common Stock on January 5, 2023, the stock issuance date.
F3	Option was granted on January 5, 2023 and awarded in accordance with the 2019 Plan. Option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.